The Nature of the Drug: Invokana is a drug prescribed to treat Type 2 (adult onset) diabetes. It was developed by the Japanese company Mitsubishi Tanabe Pharma, and is marketed in the United States by Janssen, a division of Johnson & Johnson. Invokana belongs to the class of drugs called subtype 2 sodium-glucose transport (SLGT-2) inhibitors, which work by encouraging the kidneys to release more sugar into the urine as a way of managing blood-sugar level.

The Hazards of Invokana: Invokana users have reported numerous mild to severe side effects, the most common of which is diabetic ketoacidosis, a condition in which the body can no longer use glucose to fuel cellular functions. Symptoms of the potentially fatal condition include loss of feeling in the toes or feet, dizziness or fainting, confusion, extreme fatigue or weakness, difficulty breathing, nausea, vomiting, chest pain, abdominal pain, and elevated heart rate.

Invokana users are at increased risk of urinary-tract infection, which becomes a risk when the body releases too much sugar into the urine. A severe urinary-tract infection can damage the kidneys or spread to other parts of the body.

Some Invokana users have experienced nausea, increased urination, yeast infections, and increased thirst. Other rare but serious conditions that have been linked to the drug are kidney failure and amputation of a foot or leg.
The damage done by diabetic ketoacidosis and other serious side effects of Invokana have given rise to numerous lawsuits against Janssen. Other SLGT-2 inhibitor drugs are also the subject of lawsuits and FDA warnings.

To Obtain Legal Relief: People who have taken Invokana or another SLGT-2 inhibitor drug, and who suffer from diabetic ketoacidosis or another serious medical condition, may have valuable legal rights. Attorney Stephen A. Katz is available at (800) 251-3529 for a free consultation, or for legal representation.